

May 30, 2018



Humanigen CEO to Present at 8th Annual LD Micro Invitational

BURLINGAME, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- [Humanigen, Inc.](http://www.humanigen.com) (OTCQB:HGEN), a biopharmaceutical company developing cutting-edge T-cell optimization and oncology treatments, today announced that Cameron Durrant, M.D., chairman and CEO, will present a company overview at the 8th Annual LD Micro Invitational on Monday, June 4, 2018, at 4 p.m. PDT (7 p.m. EDT).

Dr. Durrant will discuss Humanigen's focus to enhance T-cell therapies in oncology with its proprietary Humaneered[®] monoclonal antibodies, including lead asset lenzilumab as a potential prophylactic therapy to optimize treatment and minimize or prevent neurotoxicity associated with chimeric antigen receptor T-cell (CAR-T) therapy. Lenzilumab is a first-in-class recombinant monoclonal antibody that targets and is an antagonist of soluble granulocyte-macrophage colony-stimulating factor (GM-CSF), an upstream druggable target for inflammatory cascade side effects caused by CAR-T treatments.

A live webcast of the presentation will be available at <http://www.wsj.com/webcast/ldmicro14/hgen/>. Following the conference, an archived version of the webcast will be available 120 days for replay on the Humanigen website at <https://ir.humanigen.com/events>.

For more information on the conference, please visit <https://www.ldmicro.com/events>.

About Humanigen

Humanigen, Inc. is a biopharmaceutical company developing cutting-edge T-cell optimization and oncology treatments. Derived from the company's Humaneered[®] platform, lenzilumab, ifabotuzumab and HGEN005 are monoclonal antibodies with first-in-class mechanisms. Lenzilumab, which targets GM-CSF, is in development as a potential medicine to make CAR-T therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Ifabotuzumab, which targets Eph receptor A3 (EphA3), is being explored as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers, as well as a backbone for a novel CAR-T construct and bispecific antibody platform. HGEN005, which targets human epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1), has potential as a treatment for eosinophilic diseases, such as a novel CAR-T construct for eosinophilic leukemia. For more information, visit www.humanigen.com.

CONTACT:

Investors:

Al Palombo

650-243-3181

ir@humanigen.com

Media:

media@humanigen.com



Source: Humanigen, Inc